Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Current Assets: 2014-2025

Historic Current Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $571.9 million.

  • Viridian Therapeutics, Inc.\DE's Current Assets fell 25.47% to $571.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $571.9 million, marking a year-over-year decrease of 25.47%. This contributed to the annual value of $738.5 million for FY2024, which is 51.80% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Current Assets stood at $571.9 million, which was down 1.18% from $578.8 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Current Assets ranged from a high of $767.4 million in Q3 2024 and a low of $115.5 million during Q2 2021.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Current Assets averaged around $551.0 million, with its median value being $578.8 million (2025).
  • Its Current Assets has fluctuated over the past 5 years, first soared by 581.66% in 2021, then declined by 25.96% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Current Assets (Quarterly) stood at $200.2 million in 2021, then surged by 115.41% to $431.2 million in 2022, then increased by 12.83% to $486.5 million in 2023, then surged by 51.80% to $738.5 million in 2024, then decreased by 25.47% to $571.9 million in 2025.
  • Its last three reported values are $571.9 million in Q3 2025, $578.8 million for Q2 2025, and $657.2 million during Q1 2025.